EBS up +6.49% percent right now. $EBS High is at 24.46 and

New Post Public Reply Private Reply Replies (0) Message Board

Nov 9, 2014 at 2:54 PM

EBS up +6.49% percent right now. $EBS High is at 24.46 and the Low 23.32 with current volume of 558,700.

Recent News posted below.

EBS Emergent Biosolutions Recent Headline News

Emergent Biosolutions posts 3Q profit
Automated Insights - Fri Nov 07, 4:04AM CST
ROCKVILLE, Md. (AP) _ Emergent Biosolutions Inc. (EBS) on Friday reported earnings of $21.8 million in its third quarter.
EBS: 23.95 (+1.46)

Emergent BioSolutions Inc Busts Through Guidance. Sort of.
Brian Orelli, The Motley Fool - Motley Fool - Thu Nov 06, 7:39PM CST
Considering that Emergent BioSolutions has regular government contracts and other manufacturing contracts -- so regular that it's willing to give quarterly guidance, which many companies wouldn't dream of -- it was a little surprising to see by...
EBS: 23.95 (+1.46)

Emergent BioSolutions Reports Third Quarter and Nine Month 2014 Financial Results
GlobeNewswire - Thu Nov 06, 3:01PM CST
Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and nine months ended September 30, 2014. Financial highlights included:
EBS: 23.95 (+1.46)

3 Biotech Stocks With Humongous Short Interest
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 22, 8:05AM CDT
Buying when everyone else is scared may sound like a fantastic way to buy great companies at bargain-basement prices, but it can be tricky to figure out when there's enough fear to justify buying, especially in hit-and-miss industries...
EBS: 23.95 (+1.46), NLNK: 32.15 (-2.54), TEVA: 57.70 (-1.02), AMRI: 16.84 (+0.75)

Amicus Reports Additional Positive Data on Fabry Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 5:35PM CDT
Amicus Therapeutics, Inc. (FOLD) announced additional positive data from a phase III study (Study 011) on migalastat, for treating Fabry disease patients.
HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), SNY: 45.69 (-0.17), FOLD: 5.72 (-0.16)

Affymetrix-Ariosa Ink Supply Deal for Harmony Prenatal Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 3:55PM CDT
Affymetrix Inc. (AFFX) announced that it has entered a multi-year supply agreement with San Jose, California-based Ariosa Diagnostics, Inc.
EBS: 23.95 (+1.46), FCSC: 2.73 (+0.06), EXAS: 22.82 (-0.52), AFFX: 9.43 (-0.02)

Emergent BioSolutions (EBS) Jumps: Stock Moves Up 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 7:51AM CDT
Emergent BioSolutions, Inc. (EBS) was a big mover last session, as its shares rose nearly 6% on the day.
MACK: 8.70 (-0.07), HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), EXAS: 22.82 (-0.52)

Emergent BioSolutions to Webcast Presentation at Credit Suisse 2014 Healthcare Conference
GlobeNewswire - Mon Oct 20, 6:08AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company will be webcasting its presentation at the Credit Suisse 2014 Healthcare Conference in Phoenix, Arizona on Tuesday, November 11, 2014 at 8:00 AM Mountain. During the presentation, a member of the company's management team will provide a corporate overview, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcast of this presentation will be available both live and by replay, accessible from the Emergent website www.emergentbiosolutions.com under "Investors."
EBS: 23.95 (+1.46)

Ultragenyx Reports Data from Sialic Acid Deficiency Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 4:00PM CDT
Ultragenyx Pharmaceutical Inc. (RARE) reported interim data from a phase II extension study on sialic acid extended-release tablets.
HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), RARE: 44.71 (-0.15), LGND: 53.94 (-0.97)

Infinity Pharmaceuticals' Duvelisib Fails in Mid-Stage Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 4:00PM CDT
Infinity Pharmaceuticals (INFI) announced disappointing results from a phase IIa study on duvelisib.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), INFI: 13.01 (+0.87), ABBV: 61.50 (-1.21)

Gilead's Harvoni Receives Notice of Compliance from Canada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 3:30PM CDT
Health Canada issued a notice of compliance to Gilead's (GILD) Harvoni.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21)

What Falling Estimates & Price Mean for Enzo Biochem (ENZ) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:57AM CDT
Enzo Biochem stock could bring additional losses for your portfolio
HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), ENZ: 4.94 (-0.13), EPZM: 23.75 (+0.19)

Alexion (ALXN) Seeks Japanese Approval for Asfotase Alfa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 3:30PM CDT
Alexion (ALXN) has filed a new drug application for asfotase alfa in Japan.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), ALXN: 193.81 (+0.67), LGND: 53.94 (-0.97)

Agios (AGIO) Rises on Expansion of Phase I Study on AG-221 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 3:10PM CDT
Agios Pharmaceuticals (AGIO) initiated four expansion cohorts in its ongoing phase I study on AG-221.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), AGIO: 72.06 (-11.03), CELG: 106.45 (-0.69)

GW Pharmaceuticals Down on Disappointing Mid-Stage Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 5:48PM CDT
GW Pharmaceuticals (GWPH) announced disappointing results from a phase IIa study on GWP42003.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), GWPH: 73.97 (-0.41), LGND: 53.94 (-0.97)

Novavax Begins Mid-Stage Study on RSV Vaccine in Elders - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 4:20PM CDT
Novavax (NVAX) initiates phase II study on RSV vaccine.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), GILD: 106.45 (-0.49), NVAX: 4.95 (-0.20)

Alnylam Reveals Positive Data from its Pipeline Candidates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 3:30PM CDT
Alnylam Pharmaceuticals (ALNY) announced several study results on its pipeline candidates.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), ALNY: 95.84 (+2.93), LGND: 53.94 (-0.97)

Alnylam Jumps on Positive Patisiran Data from Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 3:45PM CDT
Alnylam (ALNY) revealed encouraging initial results from an ongoing phase II study on patisiran.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), ALNY: 95.84 (+2.93), LGND: 53.94 (-0.97)

Protalix BioTherapeutics, Inc. (PLX) in Focus: Stock Surges 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 8:18AM CDT
Protalix BioTherapeutics, Inc. (PLX) was a big mover last session, as the company saw its shares rise by over 7% on the day.
EBS: 23.95 (+1.46), FCSC: 2.73 (+0.06), PLX: 2.04 (-0.01), EPZM: 23.75 (+0.19)

Alnylam Pharmaceuticals (ALNY) Jumps: Stock Rises 19% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 8:04AM CDT
Alnylam Pharmaceuticals, Inc. (ALNY) was a big mover last session, as the company saw its shares rise almost 19% on the day.
EBS: 23.95 (+1.46), ALNY: 95.84 (+2.93), FCSC: 2.73 (+0.06), EPZM: 23.75 (+0.19)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Survivors Secure $800M Settlement with NY Archdiocese

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Vantrue's Black Friday Dash Cam Deals: Save up to 44%

Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...

Sinclair Faces Labor Lawsuit for Break-time Violations

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Ping An's Bold Green Moves Ahead of APEC 2026

By Owen Jenkins Updated Oct 25, 2026 Category News Views 175

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Miranda Lambert Lights Up Red Kettle Campaign

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Spooky Dining at CARNE: A Halloween Hit in Oxnard

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...